CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma

Published:2016-09-16 Issue:12 Volume:5 Page:e1231290
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Cubillos-Zapata Carolina,Cordoba Raúl,Avendaño-Ortiz José,Arribas-Jiménez Cristina,Hernández-Jiménez Enrique,Toledano Víctor,Villaescusa Teresa,Moreno Víctor,López-Collazo Eduardo

Funder

“Fondos de Investigación Sanitaria” (FIS)

FEDER

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2016.1231290

Reference15 articles.

1. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

2. Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment

3. Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide

4. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

5. Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanistic Basis and Role of Immunomodulatory Drugs;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21

2. Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy;Biomedicine & Pharmacotherapy;2023-11

3. Recent advances in the pharmacological targeting of ubiquitin-regulating enzymes in cancer;Seminars in Cell & Developmental Biology;2022-12

4. Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms;Frontiers in Immunology;2022-10-12

5. Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma;eJHaem;2022-02-14